EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment

Anthéa Deschamps, Florence Gattacceca, Olivier Blin, Lionel Velly, Romain Guilhaumou

Clinical Pharmacokinetics · 2026-11 · 65 (11) · 1771-1784

DOI: 10.1007/s40262-026-01701-w ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 30.09.2026. Verfasst von Anthéa Deschamps und 4 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, APHM, INSERM, Service de Pharmacologie Clinique et Pharmacosurveillance, Marseille, France. anthea.deschamps@ap-hm.fr. Hauptthemen laut MEDLINE: Cefotaxime, Anti-Bacterial Agents, Critical Care. Die Arbeit nennt 73 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cefotaxime is a beta-lactam antibiotic commonly used in critically ill patients. In this population, pathophysiological features induce high inter- and intra-individual pharmacokinetic variability that can result in supra or sub-therapeutic concentrations of cefotaxime. However, factors leading to variability during the treatment course remain poorly described. OBJECTIVE: The objective of the present study was to characterize the pharmacokinetics of cefotaxime and associated inter- and intra-individual variability in order to optimize individual dosing regimens for adult intensive care patients. Simulations based on the population pharmacokinetic model characterized the impact of these covariates on pharmacokinetic/pharmacodynamic target attainment. METHODS: Adult intensive care patients were included in a prospective observational study. Cefotaxime concentrations were measured 30 min after the loading dose, during the continuous infusion at days 1, 4, and 7 after drug initiation, and 4 h after the end of infusion. Pharmacokinetic analyses were performed using a parametric population approach. The impact of covariates was determined by combining a baseline covariate model with a time-varying covariate model. Monte Carlo simulations were performed to evaluate the probability of target attainment for different dosing regimens, with a pharmacokinetic/pharmacodynamic target of 100% of the time with cefotaxime free concentration over the minimal inhibitory concentration. RESULTS: The study included 76 intensive care patients (251 cefotaxime plasma concentrations). A one-compartment model with linear elimination and proportional residual error best described the data. Serum albumin concentration, age, sex, and time-varying serum creatinine concentration were identified as significant covariates. Simulations based on the final model showed that the recommended dosing regimen (2-g loading dose followed by 6 g per day) only achieves pharmacokinetic/pharmacodynamic targets for a minimal inhibitory concentration ≤1 mg/L. As a consequence of serum creatinine concentration intra-individual variability, observed probability of target attainment decreased with time: 59.3, 56.4, and 50.7%, respectively at days 1, 4, and 7, for patients with a baseline serum creatinine concentration between 100 and 150 µmol/L. For minimum inhibitory concentration values above 1 mg/L, an initial dosing regimen of a 2-g loading dose followed by 10 g per day could be appropriate. CONCLUSIONS: A population pharmacokinetic model of cefotaxime was developed to determine both inter- and intra-individual variability in intensive care patients and was applied to evaluate the impact of various dosing regimens on pharmacokinetic/pharmacodynamic target attainment. Serum creatinine concentration explained a significant part of the observed inter- and intra-individual pharmacokinetic variability and a biomarker model would be helpful to anticipate serum creatinine concentration evolution and improve the prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefotaximeAnti-Bacterial AgentsCritical CareHumansFemaleMaleMiddle AgedProspective StudiesAgedMonte Carlo MethodModels, BiologicalAdultSecond Generation CephalosporinsDose-Response Relationship, DrugCritical Illness

Substanzen

CefotaximeAnti-Bacterial AgentsSecond Generation Cephalosporins

Autor:innen und Institutionen

  • Aix Marseille University, APHM, INSERM, Service de Pharmacologie Clinique et Pharmacosurveillance, Marseille, France. anthea.deschamps@ap-hm.fr.
  • COMPutational Pharmacology and Clinical Oncology Department, Inria Sophia Antipolis-Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France. ant…
  • COMPutational Pharmacology and Clinical Oncology Department, Inria Sophia Antipolis-Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France.
  • Aix Marseille University, APHM, INSERM, Service de Pharmacologie Clinique et Pharmacosurveillance, Marseille, France.
  • Department of Anaesthesiology and Critical Care Medicine, Aix Marseille University, APHM, University Hospital Timone, Marseille, France.
  • Aix Marseille University, CNRS, INT, Institute Neuroscience Timone, UMR7289, Marseille, France.

Zitieren

APA

Deschamps, A., Gattacceca, F., Blin, O., Velly, L., & Guilhaumou, R. (2026). Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment. Clinical Pharmacokinetics, 65(11), 1771-1784. https://doi.org/10.1007/s40262-026-01701-w

Vancouver

Deschamps A, Gattacceca F, Blin O, Velly L, Guilhaumou R. Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment. Clinical Pharmacokinetics. 2026;65(11):1771-1784. doi:10.1007/s40262-026-01701-w

BibTeX
@article{Deschamps2026,
  author = {Deschamps, Anthéa and Gattacceca, Florence and Blin, Olivier and Velly, Lionel and Guilhaumou, Romain},
  title = {Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {11},
  pages = {1771--1784},
  doi = {10.1007/s40262-026-01701-w}
}
Kostenlos starten →